Kiadis Pharma is a clinical stage biopharmaceutical company
developing innovative and potentially life‑saving therapies for
patients with late stage blood cancers and related disorders in
need of a transplant, an area of significant unmet medical need.
ATIR™ is Kiadis Pharma’s lead product in development and enables partially
matched stem cells from family members (haploidentical donors) to be used
in reconstituting the immune system of blood cancer patients after a bone
marrow transplantation without eliciting severe or life threatening Graft-versus-Host-Disease (GvHD).
The Company is currently sponsoring a multi‑center Phase II
clinical trial for ATIR™ and is collaborating with renowned centers in Europe and North America.
May 13, 2015EMA grants Kiadis Pharma’s lead product ATIR™ ATMP certificate for quality and non-clinical data
May 7, 2015Kiadis Pharma appoints Dr. Vincent Brichard to its Supervisory Board
December 9, 2014Kiadis Pharma presents positive data from a pre-specified interim analysis of the Phase II clinical program with its lead product ATIR™
October 30, 2014Kiadis Pharma’s lead product ATIR™ granted Orphan Drug Designation by EMA for the treatment of Acute Myeloid Leukemia
Interview with Denis-Claude Roy, MD
Denis-Claude Roy, MD, Professor of Medicine at the University of Montreal, talks about ATIR™ at the 2014 annual meeting of American Society of Hematology
Advanced Therapies Investor Day
Watch the company presentation by Manfred Rüdiger, CEO of Kiadis Pharma, at the Advanced Therapies Investor Day held November 13, 2014 in London, UK
The Company Fact Sheet provides a valuable insight into where Kiadis Pharma stands today.
It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development.